Skip to main content
TipRanks
Go Ultimate75% OFF

Mangalam Drugs & Organics Ltd. (MANGALAM) Stock Price & Analysis

1 Followers

MANGALAM Stock Chart & Stats

₹28.67-₹0.96(-3.24%)
At close: 3:30 PM GMT+5:30
₹27.5₹30₹32.5₹35Aug 24Sep 7Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
INR 28.28 - INR 28.75
52-Week Range
INR 22.70 - INR 58.78
Previous Close
INR 29.63
Volume
15.57K
Average Volume (3M)
2,411
Market Cap
INR 468.99M
Enterprise Value
INR 1.38B
Total Cash (Recent Filing)
INR 8.35M
Total Debt (Recent Filing)
INR 903.89M
Price to Earnings (P/E)
―
Beta
0.56
Next Earnings
Feb 14, 2027 (Est.)
EPS Estimate
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Specialty Intermediate Business

The company serves pharmaceutical and broader chemical value chains with specialized intermediates rather than undifferentiated consumer products. This industrial positioning can support recurring demand across multiple applications and provides a platform for higher-value downstream derivatives over the medium term.

Positive Equity Base And Asset Scale

Positive net worth and a sizable asset base provide an operating foundation despite the recent downturn. These resources can support continued manufacturing activity and give management more flexibility than a balance sheet with negative equity, provided leverage and profitability stabilize.

Demonstrated Profitability And Cash Generation

Historical profitability and periods of solid operating cash generation show that the business has previously converted its operations into earnings and cash. This evidence supports the possibility of recovery if demand, product mix, utilization, and operating efficiency improve from current levels.

Bears Say

Sharp Profitability Deterioration

The move from modest FY2025 profitability to a substantial FY2026 loss indicates that earnings are currently highly vulnerable to operating conditions. Negative operating margins reduce internal funding capacity and make a durable recovery dependent on restoring profitable production and sales.

Revenue Contraction

A multi-year pattern of declining revenue suggests more than a single-period earnings disruption and raises concern about demand, volumes, pricing, or product mix. Continued contraction would weaken fixed-cost absorption, restrict investment capacity, and make margin recovery harder to sustain.

Weak Cash Generation And Higher Leverage

Negative operating and free cash flow leave less internally generated funding for operations, investment, and debt service. Combined with materially higher leverage, this increases financial pressure and reduces flexibility if weak profitability or cash conversion persists over the next several quarters.

Mangalam Drugs & Organics Ltd. News

MANGALAM FAQ

What was Mangalam Drugs & Organics Ltd.’s price range in the past 12 months?
Mangalam Drugs & Organics Ltd. lowest stock price was ₹22.70 and its highest was ₹58.78 in the past 12 months.
What is Mangalam Drugs & Organics Ltd.’s market cap?
Mangalam Drugs & Organics Ltd.’s market cap is ₹468.99M.
When is Mangalam Drugs & Organics Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Mangalam Drugs & Organics Ltd.’s earnings last quarter?
Mangalam Drugs & Organics Ltd. released its earnings results on Nov 05, 2026. The company reported -₹4.554 earnings per share for the quarter.
Is Mangalam Drugs & Organics Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Mangalam Drugs & Organics Ltd. pay dividends?
Mangalam Drugs & Organics Ltd. pays a dividend of ₹0.5 which represents an annual dividend yield of ―. See more information on Mangalam Drugs & Organics Ltd. dividends here
What is Mangalam Drugs & Organics Ltd.’s EPS estimate?
Mangalam Drugs & Organics Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Mangalam Drugs & Organics Ltd. have?
Mangalam Drugs & Organics Ltd. has 15,828,248 shares outstanding.
What happened to Mangalam Drugs & Organics Ltd.’s price movement after its last earnings report?
Mangalam Drugs & Organics Ltd. reported an EPS of -₹4.554 in its last earnings report. Following the earnings report the stock price went up 3.22%.
Which hedge fund is a major shareholder of Mangalam Drugs & Organics Ltd.?
Currently, no hedge funds are holding shares in IN:MANGALAM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology